Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension

Medical University of Vienna

Status: Enrolling

Conditions: Blood Pressure, High; Arterial Hypertension

Study type: Observational

Funder types: Other

Identifiers

NCT06098300

OPHT-240323

Details and patient eligibility

About

To evaluate whether in patients with initially poorly-controlled arterial hypertension, structural and functional differences in the retina and choroid remain after achieving a well-controlled blood pressure.

Full description

Optical Coherence Tomography Angiography (OCT-A) is an ocular imaging technique which allows fast and non-invasive assessment of the retinal microvasculature. With the OCT-A, a reduction in capillary density in patients with arterial hypertension has been found. In animal experiments, this so called retinal capillary rarefaction could be reversed after administration of antihypertensive medication.

The main aim of the present study is to evaluate whether in patients with initially poorly-controlled hypertension, an increase in capillary density can be demonstrated, if patients achieve well-controlled blood pressure with antihypertensive medication. In addition changes in retinal oxygen metabolism and choroidal blood flow will be investigated.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and Women aged ≥ 18 years
• Signed informed consent
• Apart from hypertensive retinopathy, normal ophthalmic findings
• Non-Smokers
• Patients with initially diagnosed or pre-existing mild to moderate primary arterial hypertension (systolic office blood pressure ≥ 140 mmHg and/or diastolic office blood pressure ≥ 90 mmHg)
• Planned initiation of antihypertensive medication or planned adaption of antihypertensive medication by the Department of Cardiology
• Subject agrees to perform regular blood pressure self-measurements and to document blood pressure values in a diary

Exclusion criteria

• Participation in a clinical trial in the three weeks preceding the study
• Blood donation in the three weeks preceding the study
• Symptoms of a clinically relevant illness in the three weeks preceding the study
• History of family history of epilepsy
• Secondary hypertension (e.g.: hyperaldosteronism, pheochromocytoma, renal artery stenosis, renal parenchymal diseases, Cushing-syndrome, Coarctatio aortae)
• History of hypertensive encephalopathy or intracerebral bleeding
• Diabetes mellitus Type 1 or Type 2
• Pregnant or breast-feeding women
• Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception